Angiotensin‐converting enzyme inhibitors vs placebo or no treatment: Micro‐ to normoalbuminuria Median
It is very uncertain whether angiotensin‐converting‐enzyme inhibitors changes micro‐ to normoalbuminuria Median compared with placebo or no treatment (very low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Angiotensin‐converting‐enzyme inhibitors vs placebo or no treatment Micro‐ to normoalbuminuria Median · people with diabetes and kidney disease It is very uncertain whether angiotensin‐converting‐enzyme inhibitors changes micro‐ to normoalbuminuria Median compared with placebo or no treatment (very low certainty). Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane Headline outcomes only | RR 3.01 [1.86, 4.88] | 17 studies · 1959 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease 2024 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.